CADL

insider transactions

Candel Therapeutics, Inc. — buys & sells by directors, officers and 10% owners (SEC Form 4).

30D 90D 1Y

Net shares · 365d

+550.5K

550.5K buy · 0 sell

Net value · 365d

$3.0M

$3.0M in · $0 out

Sentiment · 365d

Net buying

100% buying · 0% selling

Open-market trades · 365d

550.5K buy · 0 sell

Net buy / sell volume

Tap or hover the chart for daily net volume. Green = net buying, red = net selling.

All transactions

Grant·A
Mar 31, 26

Nicoletta Loggia

Director

$3.2K

779 sh · $4.11

Own New
Grant·A
Mar 31, 26

Paul B Manning

Director

$19.0K

4.6K sh · $4.11

Own New
Grant·A
Mar 31, 26

Joseph C Papa

Director

$11.5K

2.8K sh · $4.11

Own New
Buy·P
Feb 23, 26

Paul B Manning

Director

$3.0M

550.5K sh · $5.45

Own +25%
Grant·A
Jan 26, 26

Seshu Tyagarajan

Chief Technology Officer

$0

154.0K sh

Own New
Grant·A
Jan 26, 26

William Garrett Nichols

Chief Medical Officer

$0

136.5K sh

Own New
Grant·A
Jan 26, 26

Charles Schoch KEY

Chief Financial Officer

$0

232.0K sh

Own New
Grant·A
Jan 26, 26

Tak Paul Peter KEY

Chief Executive Officer

$0

629.0K sh

Own New
Grant·A
Jan 26, 26

Francesca Barone

Chief Scientific Officer

$0

232.0K sh

Own New

Date▾	Insider	Role	Type	Shares	Own Δ	Price	Value
Mar 31, 2026	Nicoletta Loggia	Director	Grant A	779	New	$4.11	$3.2K
Mar 31, 2026	Paul B Manning	Director	Grant A	4.6K	New	$4.11	$19.0K
Mar 31, 2026	Joseph C Papa	Director	Grant A	2.8K	New	$4.11	$11.5K
Feb 23, 2026	Paul B Manning	Director	Buy P	550.5K	+25%	$5.45	$3.0M
Jan 26, 2026	Seshu Tyagarajan	Chief Technology Officer	Grant A	154.0K	New	—	$0
Jan 26, 2026	William Garrett Nichols	Chief Medical Officer	Grant A	136.5K	New	—	$0
Jan 26, 2026	Charles Schoch KEY	Chief Financial Officer	Grant A	232.0K	New	—	$0
Jan 26, 2026	Tak Paul Peter KEY	Chief Executive Officer	Grant A	629.0K	New	—	$0
Jan 26, 2026	Francesca Barone	Chief Scientific Officer	Grant A	232.0K	New	—	$0

About CADL insider trading

This page tracks insider transactions for Candel Therapeutics, Inc. (CADL) reported to the U.S. Securities and Exchange Commission on Form 4. Corporate insiders — directors, executive officers and beneficial owners of more than 10% of the stock — must disclose their trades within two business days. Open-market purchases (code P) and sales (code S) made at the insider's discretion are the most-watched opportunistic signals, while awards (A), option exercises (M) and tax-withholding (F) reflect compensation rather than conviction. Trades marked 10b5-1 were made under a pre-arranged plan and are considered routine. A cluster buy — several insiders buying within a short window — is historically a stronger bullish indicator than any single trade.